VeevaのMyVeeva for Patients担当ヴァイスプレジデントであるTim Davisは次のようにコメントしています。「構想からわずか6カ月で被験者に初めてVeeva eConsentを使っていただきました。将来のペーパーレスな患者中心の臨床試験に向けた大きな一歩であり、この意義あるビジョンの実現に役立つ技術革新を今後も業界にもたらしていくことに、弊社は引き続き注力していきます。」
4月29日(米国東部標準時間)に開催予定のウェビナーでは、Crofoot Research CenterからVeeva eConsentによる効率的な臨床試験の実施方法についてお話しいただき、治験依頼者と試験実施医療機関、被験者をつないで臨床試験を加速させる業界唯一のソリューション、Veeva Clinical Networkの詳細をご紹介します。
MyVeeva for Patients is a new application that clinical research sites can use to digitally connect with research patients. With capabilities for eConsent, virtual visits, patient adherence, and ePRO,
【Forward-looking Statements】
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2020.This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.